Seth Rudnick - G1 Therapeutics Chairman of the Board
| GTHX Stock | USD 4.44 0.31 7.51% |
Chairman
Dr. Seth A. Rudnick M.D. is Independent Director of G1 Therapeutics Inc. He has served as Chairman of our board of directors since May 2014 and as the Executive Chairman of our board of directors from January 2014 to May 2014. Dr. Rudnick also serves as a member of the boards of directors of several life sciences companies, including Pozen Inc., a publicly traded pharmaceutical company, and Liquidia Technologies, Inc., a privately held biotechnology company, for which he serves as Chairman of the board of directors. From 2012 until October 2015, he served as a member of the board of directors of Square 1 Financial Inc., a financial services company that was publicly traded until October 2015, and previously served on the boards of directors of more than a dozen other privately held biotechnology companies. From 1999 to December 2013, when he retired, Dr. Rudnick was a general partner at Canaan Partners, a VC firm that invests in companies in the technology and healthcare sectors. From 1986 to 1991, he was head of research and development at Johnson Johnsons biotechnology company, Ortho Biotech, and from 1982 to 1986, Dr. Rudnick was head of pharmaceutical development at Biogen N.V since 2019.
| Age | 69 |
| Tenure | 5 years |
| Professional Marks | Ph.D |
| Address | 700 Park Offices Drive, Research Triangle Park, NC, United States, 27709 |
| Phone | 919 213 9835 |
| Web | https://www.g1therapeutics.com |
G1 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1596) % which means that it has lost $0.1596 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9213) %, meaning that it created substantial loss on money invested by shareholders. G1 Therapeutics' management efficiency ratios could be used to measure how well G1 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2024. Return On Capital Employed is likely to drop to -0.45 in 2024. At this time, G1 Therapeutics' Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 121 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.9 M in 2024.Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| Robert JD | Merck Company | 57 | |
| Christopher Wilson | Invesco Trust For | 64 | |
| Robert Ready | LSI Industries | 73 | |
| Martin Flanagan | Invesco Trust For | 60 | |
| Bruce Crockett | Invesco Trust For | 76 | |
| Kenneth Frazier | Merck Company | 67 | |
Management Performance
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.16 |
G1 Therapeutics Leadership Team
Elected by the shareholders, the G1 Therapeutics' board of directors comprises two types of representatives: G1 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GTHX. The board's role is to monitor G1 Therapeutics' management team and ensure that shareholders' interests are well served. G1 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, G1 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Velleca, President CEO, Director | ||
| Jay Strum, Chief Scientific Officer | ||
| Barclay Phillips, CFO and Senior Vice President - Corporate Development | ||
| Andrew Witty, Director | ||
| Alexander MS, VP Operations | ||
| Glenn Muir, Independent Director | ||
| Jennifer Moses, Vice President - Finance and Administration | ||
| Garry Nicholson, Independent Director | ||
| ChB MB, Chief RD | ||
| Tyrell Rivers, Independent Director | ||
| John Demaree, Chief Commercial Officer | ||
| Evan MBA, Vice Marketing | ||
| Monica Thomas, General Officer | ||
| Fredric Eshelman, Independent Director | ||
| Willie Deese, Independent Director | ||
| James Hanson, General Counsel | ||
| Andrew Perry, Chief Officer | ||
| Jeff Macdonald, Head of Investor Relations/Public Relations | ||
| Jennifer CPA, Chief Officer | ||
| Cynthia Schwalm, Independent Director | ||
| Gregory Mossinghoff, Chief Business Officer, Secretary | ||
| Seth Rudnick, Chairman of the Board | ||
| Robert Uhl, IR Contact Officer | ||
| John V, Chief Officer | ||
| Rajesh Malik, Chief Medical Officer | ||
| Christy Shaffer, Independent Director | ||
| John Bailey, President CEO | ||
| William Roberts, Vice Communications | ||
| Mark Avagliano, Chief Officer | ||
| Terry Murdock, Senior Vice President - Development Operations |
GTHX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is G1 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.92 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.58) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 171.81 M | ||||
| Shares Outstanding | 52.3 M | ||||
| Shares Owned By Insiders | 11.65 % | ||||
| Shares Owned By Institutions | 30.03 % | ||||
| Number Of Shares Shorted | 2.42 M | ||||
| Price To Earning | (1.95) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in G1 Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy GTHX Stock please use our How to Invest in G1 Therapeutics guide.Note that the G1 Therapeutics information on this page should be used as a complementary analysis to other G1 Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for GTHX Stock analysis
When running G1 Therapeutics' price analysis, check to measure G1 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy G1 Therapeutics is operating at the current time. Most of G1 Therapeutics' value examination focuses on studying past and present price action to predict the probability of G1 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move G1 Therapeutics' price. Additionally, you may evaluate how the addition of G1 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is G1 Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of G1 Therapeutics. If investors know GTHX will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about G1 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.93) | Revenue Per Share 1.595 | Quarterly Revenue Growth 0.451 | Return On Assets (0.16) | Return On Equity (0.92) |
The market value of G1 Therapeutics is measured differently than its book value, which is the value of GTHX that is recorded on the company's balance sheet. Investors also form their own opinion of G1 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is G1 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because G1 Therapeutics' market value can be influenced by many factors that don't directly affect G1 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between G1 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if G1 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, G1 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.